Ceritinib - Novartis

Drug Profile

Ceritinib - Novartis

Alternative Names: LDK-378; NVP-LDK 378; NVP-LDK378-NX; Zykadia

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Diamines; Piperidines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Gastrointestinal cancer; Haematological malignancies; Solid tumours; Thyroid cancer

Most Recent Events

  • 09 Sep 2017 Novartis initiates enrolment in a phase II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03087448)
  • 05 Sep 2017 Novartis and Helsinn Therapeutics agree to co-promote ceritinib in USA for ALK-positive Non-small cell lung cancer (Metastatic disease)
  • 29 Jun 2017 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease) in Iceland, Liechtenstein, Norway, European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top